SEC Comment Letter for vTv Therapeutics (VTVT) — Jun 8, 2021
vTv Therapeutics Inc.
Date: June 8, 2021 · CIK: 0001641489 · Accession: 0000000000-21-007103
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-256755
Letter
United States securities and exchange commission logo June 8, 2021 Stephen L. Holcombe President and Chief Executive Officer vTv Therapeutics Inc. 3980 Premier Drive, Suite 310 High Point, NC 27265 Re:vTv Therapeutics Inc. Registration Statement on Form S-3 Filed June 3, 2021 File No. 333-256755 Dear Mr. Holcombe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Fredrick Philantrope at 202-551-6875 or Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lawrence G. Wee, Esq.
Show Raw Text
United States securities and exchange commission logo
June 8, 2021
Stephen L. Holcombe
President and Chief Executive Officer
vTv Therapeutics Inc.
3980 Premier Drive, Suite 310
High Point, NC 27265
Re:vTv Therapeutics Inc.
Registration Statement on Form S-3
Filed June 3, 2021
File No. 333-256755
Dear Mr. Holcombe:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Fredrick Philantrope at 202-551-6875 or Alan Campbell at 202-551-4224
with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lawrence G. Wee, Esq.